ANIP
Research Snapshot
Static fundamentals, valuation context, and investor signals for ANI PHARMACEUTICALS, INC (ANIP).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
14.4%
ROIC, 19.4% FCF margin
Growth
33.5%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 2.7x current ratio
Superinvestors
1
Top: Polen Capital Management (0.0%)
Strengths to research
- Revenue compounded at 33.5% over five years.
- Free cash flow compounded at 79.8% over five years.
- Free cash flow margin is healthy at 19.4%.
- Debt/equity looks manageable at 0.0x.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ANIP.
Grade C
46
/ 100
Financial Charts
No financial data available for ANIP (annual).
1 superinvestors own ANIP
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 6,409 | $493,000 | 0.00% | 0.0% |